Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Olaparib|DRUG: Paclitaxel and Carboplatin
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Collaborators: AstraZeneca|Cancer Research UK